ARK Invest’s Bold Moves: Loading Up on CRISPR and Beam While Dumping Teradyne and Roku

ARK Invest just reshuffled its innovation portfolio in a major way—doubling down on genetic editing while cutting ties with two tech favorites.

The Genetic Gambit

Cathie Wood's firm went all-in on CRISPR and Beam Therapeutics, betting big on the gene-editing revolution that's rewriting medicine itself. These aren't just stocks—they're tickets to the future of healthcare.

Tech Purge

Meanwhile, Teradyne and Roku got the axe. The automation testing specialist and streaming pioneer suddenly found themselves on the wrong side of ARK's disruptive vision. Sometimes even tech darlings lose their shine when newer, shinier innovations emerge.

Wood continues placing billion-dollar bets on technologies that could redefine entire industries—because when you're playing with other people's retirement money, why not aim for the genetic stars?

TLDR

• ARK Invest bought 162,327 shares of CRISPR Therapeutics worth $10.06 million on November 4, 2025, split between ARKK and ARKG funds.
• The firm purchased 291,001 shares of Beam Therapeutics valued at $7.06 million, showing confidence in gene-editing companies.
• ARK sold 27,423 shares of Teradyne worth $5.02 million through ARKK, continuing recent semiconductor testing stock reductions.
• The investment firm trimmed its Roku position by 15,362 shares valued at $1.67 million through ARKK.
• ARK sold 20,485 shares of SoFi Technologies for $627,455 through ARKF while adding $1.20 million in Bullish shares across multiple ETFs.

Cathie Wood’s ARK Invest made major changes to its portfolio on November 4, 2025, buying heavily into biotech companies while reducing positions in technology and fintech stocks. The daily trading report revealed a clear shift in focus toward gene-editing firms.

ARK purchased 162,327 shares of CRISPR Therapeutics for about $10.06 million. The buy was split between the ARK Innovation ETF and the ARK Genomic Revolution ETF.

CRISPR Therapeutics AG, CRSP

The investment firm also acquired 291,001 shares of BEAM Therapeutics valued at $7.06 million. This purchase went through the same two funds, showing ARK’s commitment to the gene-editing sector.

Both CRISPR and Beam work in the gene-editing field. These buys demonstrate ARK’s belief in genomic medicine’s future growth potential.

ARK added 23,963 shares of Bullish worth $1.20 million across several ETFs. This MOVE increased the firm’s holdings in digital assets.

Tech Stock Sales

On the selling side, ARK reduced its Teradyne position by 27,423 shares worth $5.02 million through ARKK. This continues a pattern of profit-taking in semiconductor testing stocks from the previous week.

The firm sold 15,362 shares of Roku valued at $1.67 million through the ARKK ETF. This marks another round of reductions in the streaming platform company.

Fintech Trimming

ARK sold 20,485 shares of SoFi Technologies for about $627,455 through the ARK Fintech Innovation ETF. This represents a small reduction in the firm’s fintech holdings.

The total biotech purchases of approximately $17.12 million far exceeded the sales in other sectors. The gene-editing investments accounted for the majority of ARK’s trading activity for the day.

The ARKK and ARKG funds handled most of the biotech purchases. These funds focus on innovation and genomic revolution themes respectively.

ARK’s trading activity on November 4 showed a clear preference for life sciences over technology. The firm moved capital from established tech stocks into emerging biotech companies.

The Teradyne sale extended recent reductions in semiconductor-related holdings. ARK has been adjusting its exposure to tech hardware stocks over recent weeks.

The Roku trimming continues a pattern of reducing streaming platform exposure. ARK has been gradually decreasing its stake in the company through multiple sales.

The CRISPR and Beam purchases represent ARK’s largest moves of the day. These two transactions dominated the firm’s trading volume and dollar value for November 4, 2025.